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Abstract. 
 
Integrin-mediated leukocyte adhesion is a 
critical aspect of leukocyte function that is tightly regu-
lated by diverse stimuli, including chemokines, antigen 
receptors, and adhesion receptors. How cellular signals 
from CD31 and other adhesion ampliﬁers are inte-
grated with those from classical mitogenic stimuli to 
regulate leukocyte function remains poorly understood. 
Here, we show that the cytoplasmic tail of CD31, an im-
portant integrin adhesion ampliﬁer, propagates signals 
that induce T cell adhesion via 
 
b
 
1 (VLA-4) and 
 
b
 
2 
(LFA-1) integrins. We identify the small GTPase, Rap1, 
as a critical mediator of this effect. Importantly, CD31 
selectively activated the small Ras-related GTPase, 
Rap1, but not Ras, R-Ras, or Rap2. An activated Rap1 
mutant stimulated T lymphocyte adhesion to intercellu-
lar adhesion molecule (ICAM) and vascular cell adhe-
sion molecule (VCAM), as did the Rap1 guanine nucle-
otide exchange factor C3G and a catalytically inactive 
mutant of RapGAP. Conversely, negative regulators of 
Rap1 signaling blocked CD31-dependent adhesion. 
These ﬁndings identify a novel important role for Rap1 
in regulating ligand-induced cell adhesion and suggest 
that Rap1 may play a more general role in coordinating 
adhesion-dependent signals during leukocyte migration 
and extravasation. Our ﬁndings also suggest an alterna-
tive mechanism, distinct from interference with Ras-
proximal signaling, by which Rap1 might mediate trans-
formation reversion.
Key words: guanine nucleotide exchange factor • ex-
travasation • leukocyte function-associated antigen 1 • 
integrin-mediated adhesion • lymphocyte
 
Introduction
 
In addition to soluble mitogenic stimuli, a number of leu-
kocyte cell surface molecules have been shown to regulate
integrin-mediated leukocyte adhesion. One particular re-
ceptor, CD31, a platelet endothelial cell adhesion mole-
cule (PECAM-1)
 
1 
 
(Newman, 1997), stimulates integrin-
dependent adhesion in a wide variety of vascular cells,
including leukocytes and platelets, via a process termed
adhesion amplification (Tanaka et al., 1992; Berman and
Muller, 1995; Berman et al., 1996; Ranger et al., 1997). Nu-
merous studies have also demonstrated a critical role for
CD31 in mediating integrin-dependent leukocyte chemo-
taxis and extravasation in vitro and in vivo (Berman et al.,
1996; Newman, 1997; Duncan et al., 1999). The molecular
basis for this has remained obscure, but recent studies
have demonstrated that, in addition to mediating ho-
 
mophilic cell adhesion (Newton et al., 1997), CD31 acts
as an adhesion-dependent signaling receptor (Newman,
1997; Newton et al., 1997; Pumphrey et al., 1999). CD31 li-
gation stimulates tyrosine phosphorylation of CD31, lead-
ing to its association with a number of cytoplasmic signal-
ing proteins, including SHP-1, SHP-2, SHIP, and PLC-
 
g
 
1,
suggesting that CD31 functions as a dynamic modulator of
vascular cell behavior (Newman, 1997; Newton et al., 1997;
Pumphrey et al., 1999).
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Abbreviations used in this paper:
 
 GAP, GTPase activating protein;
GEF, guanine nucleotide exchange factor; GPI, glycosylphosphatidylino-
sitol; GST, glutathione-S-transferase; HA, hemagglutinin; ICAM, inter-
cellular cell adhesion molecule; PECAM, platelet endothelial cell adhe-
sion molecule; RBD, Ras-binding domain; VCAM, vascular cell adhesion
molecule; WT, wild-type.
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Several reports suggest a role for Ras family GTPases in
the control of integrin-mediated adhesion. Ras superfam-
ily GTPases cycle between inactive GDP-bound forms and
active GTP-bound forms, and exchange for GTP and hy-
drolysis of GTP to GDP are catalyzed by guanine nucle-
otide exchange factors (GEFs) and GTPase activating pro-
teins (GAPs), respectively (Bos, 1997, 1998). Use of active
and dominant-negative mutants of H-Ras and R-Ras has
revealed that these enzymes can regulate coupling of 
 
b
 
1
and 
 
b
 
2 integrin-dependent adhesion to T cell receptor
(TCR/CD3), interleukin-3, and chemokine receptor sig-
naling in T lymphocytes and pro-B cell leukemic cell lines
(Zhang et al., 1996; O’Rourke et al., 1998; Liu et al., 1999;
Shibayama et al., 1999; Tanaka et al., 1999). We have ex-
amined whether CD31 stimulates integrin-dependent ad-
hesion via an intracellular signaling pathway, and if so,
whether members of the Ras family were involved in this
process. We find that the cytoplasmic tail of CD31 is es-
sential for CD31-induced adhesion, and that Rap1 is spe-
cifically and selectively involved in this process.
 
Materials and Methods
 
Hemagglutinin (HA)-tagged Rap1 (Rap), RapV12, and H-RasV12 in the
mammalian expression vector pMT2HA, pRSV, and pRSV-RapN17 have
been described previously (Zwartkruis et al., 1998). pMT2HA-R-RasV38
was generated by subcloning a full-length NcoI (Klenow-filled)/XhoI frag-
ment of R-RasV38 into NotI (mung bean nuclease-digested)/XhoI-
digested pMT2HA. A SalI/NotI fragment encoding amino acids 200–297
of human RalGDS was amplified by PCR to generate pMT2HA-Ral-
GDS-RBD. pMT2-HA-RapGAP was generated by subcloning full-length
RapGAP (provided by Dr. Paul Polakis, Onyx Pharmaceuticals, Rich-
mond, CA) as a SalI/BglII fragment into pMT2HA. Catalytically inactive
RapGAP LIG was generated by mutating RapGAP amino acids 284–286
(RKR) to LIG using the Stratagene Quick site-directed mutagenesis
kit. All PCR-generated sequences were checked by DNA sequenc-
ing. pCAGGS-C3G and pSR-His-tagged Spa1 were provided by Drs.
Michiyuki Matsuda (National Institutes of Health, Tokyo, Japan) and
Masakazu Hattori (Kyoto University, Kyoto, Japan), respectively.
Jurkat T cell lines were maintained as described previously (Reedquist
and Bos, 1998). The Jurkat cell line JHM1 2.2 was provided by Dr.
Doreen Cantrell (Imperial Cancer Research Fund, London, UK), with
kind permission of Dr. Art Weiss (University of California at San Fran-
cisco, San Francisco, CA). Jurkat cells used to generate CD31 wild-type
(WT), CD31 glycosylphosphatidylinositol (GPI), and Y663/686F stable
transfectants were provided by Dr. D. Samson (University of Bath, Bath,
UK). CD31
 
1
 
 and CD31
 
2
 
 variants were established by six rounds of
MACs-sorting of parental Jurkat cells with anti-CD31 antibody 10B9. The
negative variant was transfected with CD31 WT, CD31 GPI, or CD31
Y663/686F cDNA in pCDNA3 (Jackson et al., 1997; Newton et al., 1997),
and stable polyclonal lines established by selection in G418 (1 mg/ml) and
FACS sorting. Jurkat cells were transiently transfected by electroporation
with 35 
 
m
 
g plasmid DNA. Jurkat cells (1.2 
 
3
 
 10
 
7
 
 cells/ml in 0.4 ml com-
plete media) were pulsed at 250 V and 960 
 
m
 
F with 5 
 
m
 
g TK-luciferase
plasmid DNA, construct plasmids as indicated in figure legends, and
added vector plasmid to keep DNA amounts constant. 24 h after transfec-
tion, cells were transferred to serum-free media and used 42–48 h after
transfection for adhesion assays. Subconfluent A14 and COS-7 cells were
transfected by calcium phosphate precipitation as described previously
(Zwartkruis et al., 1998).
Anti-CD3 antibody T3b was kindly provided by Dr. Hergen Spits
(Netherlands Cancer Institute, Amsterdam, The Netherlands). Antiinte-
grin 
 
b
 
2 antibody L15, activating antiintegrin 
 
b
 
1 antibody TS2/16, and acti-
vating antiintegrin 
 
b
 
2 KIM185 have been described previously (van de
Wiel-van Kemenade et al., 1992; Andrew et al., 1993). mAb 24, recogniz-
ing a ligand-induced epitope of 
 
a
 
L, was kindly provided by Dr. Nancy
Hogg (Imperial Cancer Research Fund, London, UK). Anti-CD31 anti-
bodies, PECAM 1.2 and PECAM 1.3, were generous gifts from Dr. Peter
Newman (Blood Center of Southeastern Wisconsin, Milwaukee, WS). Anti-
CD31 antibodies 2H8, WM59, GI18, and 9G11 have been described previ-
ously (Yan et al., 1995; Newton et al., 1997). Other mAbs used in these
 
studies were anti-Rap1, RalA, and Ras antibodies (Transduction Labora-
tories). Rabbit polyclonal anti-Rap2 and R-Ras antibodies were from
Santa Cruz.
Purification of GST-RBD fusion proteins and their use in detecting ac-
tivated Rap1, Rap2, Ras, and R-Ras by precipitation, SDS-PAGE, and
immunoblotting have been described previously (de Rooij and Bos, 1997;
Franke et al., 1997; Reedquist and Bos, 1998). Detection of bound radiola-
beled GDP and GTP to Rap1 was also described previously (Zwartkruis
et al., 1998).
For adhesion assays, transiently transfected Jurkat cells were har-
vested, washed, and resuspended in TSM media (20 mM Tris, pH 8, 150
mM NaCl, 1 mM CaCl
 
2
 
, 2 mM MgCl
 
2
 
). 96-well Costar Maxisorp plates
were coated overnight at 4
 
8
 
C with goat anti–human IgG antibodies (Jack-
son ImmunoResearch; 4 
 
m
 
g/ml in TSM), washed, blocked for 30 min at
37
 
8
 
C with 1% BSA/TSM, followed by incubation 1 h at 37
 
8
 
C with 50 ng/ml
recombinant intercellular adhesion molecule (ICAM)-1 or vascular cell
adhesion molecule (VCAM)-1 human IgG Fc fusion proteins. The 50-
 
m
 
l
cell suspension was mixed with 50 
 
m
 
l TSM or TSM with stimuli indicated.
Cells were allowed to adhere for 30–60 min, and nonadherent cells re-
moved with warm 0.5% BSA/TSM. Adherent cells were lysed and sub-
jected to luciferase assays as described previously (Medema et al., 1992).
Expression of transfected constructs was confirmed by immunoblotting of
total cell lysates. Cells bound were calculated and were corrected for
transfection efficiency and nonspecific effects of constructs by measuring
luciferase activity of total input cells. Comparison of effects of cDNA con-
struct overexpression on adhesion were made by paired 
 
t
 
 test or unpaired
 
t
 
 test as appropriate. Fluorescent labeling of stably transfected cells with
2’7’-bis-(2-carboxyethyl)-5-(and-6)-carboxy fluorescein acetoxymethyl es-
ter (Molecular Probes) and measurement of adherent cells with a Fluoro-
scan Ascent fluorescent plate reader (Lab Systems) has been described
previously (Newton et al., 1997).
Flow cytometric analysis of transfected cells was performed by cotrans-
fecting Jurkat JHMI cells with 1 
 
m
 
g pCMV-EGFP C1 plasmid (Promega)
and the indicated cDNA constructs. After overnight serum starvation,
cells were equilibrated in 0.5% BSA/1 mM CaCl
 
2
 
/PBS (FACS buffer) and
left unstimulated, or stimulated for 30 min with plate-immobilized anti-
CD31 antibody 2H8 (10 
 
m
 
g/ml). Cells were harvested, resuspended in
FACS buffer containing primary antibodies (10 
 
m
 
g/ml), and incubated for
30 min on ice, or 37
 
8
 
C for mAb 24 epitope expression. For mAb 24 stain-
ing, additional sets of transfected cells were coincubated with 400 
 
m
 
M
MnCl
 
2 
 
during primary antibody staining. Cells were washed with FACS
buffer and stained with secondary rabbit anti–mouse RPE-Cy5-conju-
gated antibodies (Dako). Fluorescence intensity of EGFP-transfected
cells was determined using a FACs Caliber flow cytometer and CellQuest
software (both from Becton Dickinson).
 
Results and Discussion
 
Previously, CD31 has been demonstrated to stimulate T
lymphocyte adhesion to ICAM and VCAM via T cell
LFA-1 (
 
a
 
L
 
b
 
2
 
 integrin) and VLA-4 (
 
a
 
4
 
b
 
1 
 
integrin), respec-
tively (Tanaka et al., 1992). To examine whether CD31-
stimulated integrin-dependent adhesion in T cells was reg-
ulated by signals generated through the CD31 cytoplasmic
tail or via interactions using the extracellular domain of
CD31 (Hemler, 1998), we made use of Jurkat cells stably
expressing full-length CD31 (CD31 WT), a GPI-anchored
CD31 construct, previously shown to mediate CD31 ho-
mophilic binding (Newton et al., 1997), but lacking the
CD31 cytoplasmic tail, or full-length CD31 containing two
tyrosine-to-phenylalanine mutations (Y663/686F) in the
major tyrosine-phosphorylation sites of the CD31 cyto-
plasmic tail (Pumphrey et al., 1999). CD31 expression of
parental, CD31
 
1
 
- and CD31
 
2
 
-selected variants, and stable
transfectants is shown in Fig. 1 A, and was equivalent in
CD31 WT, CD31 GPI, and Y663/686F lines. All cell lines
also expressed similar levels of 
 
a
 
L, 
 
a
 
4, 
 
a
 
5, 
 
b
 
1, and 
 
b
 
2 inte-
grins (data not shown). Although all cell lines adhered to
ICAM-1 and VCAM-1 when stimulated by PMA (data
not shown), only CD31 WT transfectants, but not CD31 
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GPI and Y663/686F cells, adhered to ICAM-1 or VCAM-1
after stimulation with anti-CD31 antibodies (Fig. 1 B).
This suggested that CD31-induced, integrin-mediated ad-
hesion requires intracellular signaling pathways generated
by the cytoplasmic tail of CD31, specifically tyrosine phos-
phorylation of tyrosine residues 663 and/or 686, but not
signaling pathways mediated by cis-interactions of the
CD31 extracellular or transmembrane domains.
To address which Ras family members, if any, might
participate in CD31 signaling, we precipitated endogenous
GTPases from lysates of CD31-stimulated Jurkat cells
with GST fusion proteins of Ras family-binding domains
(RBDs) of Raf and RalGDS, which bind with high selec-
tivity and specificty to activated Ras and Rap GTPases, re-
spectively (de Rooij and Bos, 1997; Franke et al., 1997).
Immunoblotting of precipitated GTPases provides a quali-
tative representation of GTPase activation status after cell
stimulation, corresponding to quantitative changes de-
tected using classical GDP/GTP-binding ratio techniques.
Time course analyses of Jurkat cells treated with anti-
CD31 antibodies or TPA (Fig. 2 A) surprisingly revealed a
rapid activation of the Ras-related GTPase, Rap1, by
CD31, which was maximal 2–5 min after stimulation and
decreased slowly toward basal levels after 20 min. In con-
Figure 1. CD31-dependent adhesion to ICAM and VCAM re-
quires the cytoplasmic tail of CD31. A, CD31 expression on pa-
rental, CD31 positive and negative variants and CD31 WT, CD31
GPI, and Y663/686F Jurkat cell transfectants. Cells were stained
with control antibody (open histogram) or anti-CD31 antibody
10B9 (shaded histogram) and mean fluorescent intensity (mfi)
analyzed by FACS analysis. B, Adhesion of CD31 WT, CD31
GPI, and Y663/686F Jurkat cell lines to ICAM and VCAM. Fluo-
rescently labeled cells were allowed to adhere to purified ICAM
or VCAM (2 mg/ml) coated on 96-well plates (Nunc Maxisorp) in
the absence (medium) or presence of 10 mg/ml each of anti-CD31
antibody PECAM 1.3 and goat anti–mouse antibody. Total input
and bound fluorescent cells was measured. Bars represent the av-
erage mean and error of the percent of cells bound (cells bound/
total input cells 3 100, normalized to 100% for unstimulated
cells) of two representative experiments performed in triplicate.
Figure 2. CD31 selectively activates Rap1, but not other Ras
family GTPases. A, Jurkat JHMI 2.2 cells were unstimulated (2)
or stimulated with anti-CD31 antibody PECAM 1.3 (10 mg/ml)
for the indicated times or with TPA (100 ng/ml, 5 min), lysed, and
GTP-bound GTPases were precipitated with immobilized GST
fusion proteins of RalGDS-RBD (for Rap1 and Rap2) or Raf-
RBD (for Ras and R-Ras). Bound GTPases were resolved on
SDS-PAGE, transferred to PVDF membrane, and detected by
immunoblotting with antibodies against the indicated proteins,
followed by enhanced chemiluminescence. B, Antibodies against
CD31 extracellular domains regulating cell adhesion activate
Rap1. JHMI cells were activated for 2 min with medium (2),
anti-CD3 antibody T3b (1:200) or the indicated anti-CD31 anti-
bodies (10 mg/ml), and Rap1 activation detected as in A. Fold ac-
tivation of Rap1 compared with untreated cells was obtained by
quantitating pixels from representative blots using Adobe Photo-
shop software. C, CD31-dependent activation of Rap1 requires
CD31 cytoplasmic tail. CD31 WT, CD31 GPI, and Y663/686F Jur-
kat cell lines were stimulated for 2 min with medium (2) or 10
mg/ml PECAM 1.3 antibody and activated Rap1 detected as in A.
Results shown in each panel are representative of three indepen-
dent experiments. 
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trast, whereas both Rap1 and Ras were activated by TPA,
CD31-dependent stimulation of Rap1 was highly selective
and no activation of Rap2, Ras, or R-Ras was noted at any
point during this time course. Both Rap1 and Ras, but not
the other GTPases tested, were also activated by TCR
stimulation (data not shown). GTP-bound R-Ras was de-
tected in Raf-RBD pull-downs only after longer exposures
of films, reflecting the relatively low levels of R-Ras pro-
tein expression in Jurkat cells. R-Ras protein expression
was at least tenfold lower in Jurkat cells as compared with
A431 fibroblasts, while Rap1, Rap2, and Ras levels were
relatively equivalent (Fig. 2 A, right, last two lanes).
Functional anti-CD31 antibodies against CD31 extracel-
lular domains 1 and 6 (PECAM 1.2, PECAM 1.3, and
2H8), activated Rap1 more potently than nonfunctional
antibodies (WM59, 9G11, and GI18; Fig. 2 B), correlating
with the ability of these antibodies to induce CD31-depen-
dent adhesion (Newton et al., 1997). Additionally, activa-
tion of Rap1 by anti-CD31 antibodies was observed in
CD31 WT Jurkat cell transfectants, but not CD31 GPI or
Y663/686F transfectants (Fig. 2 C), demonstrating a cor-
relative requirement for the CD31 cytoplasmic tail in the
activation of Rap1 and induction of adhesion.
As CD31 stimulation selectively activated Rap1, and
Rap1 activation correlated with CD31-dependent adhe-
sion to ICAM and VCAM, we next addressed whether
constitutive activation of Rap1 was sufficient to induce ad-
hesion. Jurkat T cells transiently transfected with a lu-
ciferase reporter plasmid and indicated cDNA constructs
were allowed to bind to immobilized recombinant ICAM
and adhering transfected cells detected by measurement
of luciferase activity. T cells expressing constitutively ac-
tive Rap1 (RapV12) or the Rap1 GEF C3G (Tanaka et al.,
1994) displayed 
 
z
 
3.5- and 3-fold increases in adhesion to
ICAM, respectively (Fig. 3 A). C3G-induced spreading
and adhesion on fibronectin has been observed previously
in 32-D cells, although involvement of Rap1 was not ex-
amined and Ras, R-Ras, or other GTPases were impli-
cated (Arai et al., 1999). Expression of either the active
form of Ras (RasV12) or R-Ras (R-RasV38) resulted in a
 
Figure 3.
 
Rap1 regulates Jurkat cell adhesion via LFA-1 (
 
b
 
2) in-
tegrin. A, Activation of Rap1 induces Jurkat cell adhesion to
ICAM. Jurkat JHMI cells were transiently transfected with 5 
 
m
 
g
PG3-TK luciferase reporter plasmid and empty vector (control)
or pMT2-HA-RapV12, H-RasV12, R-RasV38 (each 10 
 
m
 
g), Rap-
GAP-LIG (20 
 
m
 
g), or pCAGGS-C3G (10 
 
m
 
g). Cells were al-
lowed to adhere for 1 h on immobilized ICAM, washed, lysed,
and adherent cells were quantitated by luciferase assay. Bars rep-
resent the average mean binding and standard error of the per-
cent of cells bound from two to six independent experiments (in-
dicated above bars) performed in triplicate or quadruplicate, as
calculated in Fig. 1. Typically, 10–20% of control unstimulated
cells adhered to ICAM. **
 
P 
 
, 
 
0.01; *
 
P 
 
, 
 
0.05; and 
 
§
 
P 
 
, 
 
0.1,
compared with control cells by paired 
 
t
 
 test. Expression levels of
transfected GTPases and RapGAP-LIG from a representative
adhesion assay were examined by immunoblotting lysates with
anti-HA epitope antibody 12CA5 as in Fig. 2 A (insets). Blots
shown in insets are cut from a single film exposure of one immu-
noblot. B, RapGAP-LIG mutant fails to stimulate GTP-hydro-
lyis on Rap1. A14 cells were transfected with vector alone, HA-
Rap1 alone, or in combination with increasing amounts (0.3, 1,
 
2.5, and 5 
 
m
 
g) of HA-tagged RapGAP or RapGAP-LIG, as indi-
cated above top panel. Active HA-Rap1 was precipitated from
cell lysates with RalGDS-RBD and detected by 12CA5 immuno-
blotting as in Fig. 2 (top). Transfection of HA-Rap1 (middle) and
RapGAP constructs (bottom) was monitored by immunoblotting
of total cell lysates with anti-HA antibodies. C, Rap1 signaling is
required for CD31-dependent adhesion to ICAM. WT CD31
cells transfected with pG3-TK luciferase reporter plasmid and 30 
 
m
 
g
of empty vector (control) or the indicated DNA construct were
allowed to adhere to immobilized ICAM as in A after 30-min
stimulation with medium or 10 
 
m
 
g/ml anti-CD31 antibody PE-
CAM 1.3 cross-linked with goat anti–mouse antibodies. Cells
bound were quantitated using luciferase assay and the percent of
cells bound was calculated as in Fig. 1. Shown is a representative
experiment performed in quadruplicate.
 
 P 
 
values are indicated as
in A and represent transfected cell populations compared with
control unstimulated cells (medium) or CD31-stimulated control
cells. 
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lower, but detectable induction of adhesion (1.5–2-fold).
However, RasV12-stimulated adhesion was not statisti-
cally significant, RasV12 stimulated adhesion in only two
of five experiments, and RapV12-induced adhesion was al-
ways higher than that induced by RasV12 and R-RasV38,
even though the latter two constructs were expressed at
significantly higher levels than RapV12 (Fig. 3 A, left in-
set). Introduction of a RapGAP mutant (RapGAP-LIG;
Rubinfeld et al., 1991), containing a substitution of amino
acids 284–286 in the RapGAP arginine finger critical for
RapGAP catalytic activity (RKR, mutated to LIG), which,
unlike wild-type RapGAP, displays no GAP activity to-
ward Rap1 (Fig. 3 B), increased the number of ICAM-
bound cells to a similar level as observed with RapV12 and
C3G. RapGAP-LIG may perturb Rap1 signaling by dis-
placing endogenous RapGAP from a subcellular localiza-
tion required for downregulating Rap1 or may constitu-
tively associate with basally activated Rap1 and serve as
an effector protein linking Rap1 to an as yet unidentified
target.
We next examined if inhibition of Rap1 signaling would
abolish CD31-dependent adhesion to ICAM. Therefore,
we introduced a putative dominant-negative mutant of
Rap1, RapN17, into cells. RapN17 did not affect basal ad-
hesion of Jurkat cells to ICAM, but completely abolished
CD31-dependent increases in adhesion (Fig. 3 C). Al-
though the RapN17 mutation was modeled on the corre-
sponding dominant-negative mutation in H-Ras (Medema
et al., 1991), RapN17 is not considered to function as a
strict dominant-negative protein. Whereas RasN17 blocks
Ras signaling by sequestering Ras GEFs, RapN17 fails to
bind to Rap1 GEFs in vitro
 
 
 
(van den Berghe et al., 1997),
and fails to inhibit EGF-dependent activation of cotrans-
fected wild-type Rap1 in COS-7 cells (Wolthuis, R.M.F.,
and J.L. Bos, unpublished observation).
Because of uncertainties in the mechanism by which Rap-
N17 might block CD31-stimulated adhesion, we sought
independent confirmation that Rap1 was required for
CD31-induced adhesion of Jurkat cells to ICAM. Tran-
sient expression of the Rap1-specific GAP, RapGAP, re-
sulted in a strong reduction of basal adhesion to ICAM,
and significantly reduced CD31-dependent adhesion (Fig.
3 C). This result is compatible with the notion that a
Rap1GAP should decrease levels of GTP-bound Rap1
(see Fig. 3 B), but should still allow ligand-induced activa-
tion of Rap1. Finally, we used the Rap1 binding domain of
RalGDS, RBD, which binds with high affinity and speci-
ficity to GTP-bound Rap1 in vitro (Franke et al., 1997).
This fragment is hypothesized to block effector binding to
Rap1. Expression of RBD significantly abolished both
basal and CD31-induced adhesion to ICAM (Fig. 3 C).
Thus, using three independent strategies for interfering
with Rap1 signaling, overexpression of inactive Rap1,
Rap1-specific RapGAPs, and an isolated RBD of a Rap-
binding protein, these experiments demonstrate a critical
role for Rap1 in mediating CD31-induced adhesion to
ICAM.
To address whether Rap1 selectively regulated 
 
b
 
2 inte-
grins (LFA-1) on Jurkat cells, or if it was also coupled to
the regulation of 
 
b
 
1 integrins (VLA-4), we examined the
effects of activating and inactivating mutants of Rap sig-
naling on Jurkat cell adhesion to VCAM. Stimulation of
CD31 resulted in a smaller induction of adhesion to
VCAM (1.5–2-fold increase; Fig. 4 A) than observed to
ICAM, in part due to the higher basal level of adhesion
observed on VCAM (typically 30–50%, compared with
10–20% on ICAM). A similar increase was also observed
in cells expressing RapV12, C3G, and mutant RapGAP-
LIG, but not RasV12 or R-RasV38. Conversely, RapN17,
Figure 4. Rap1 mediates CD31-dependent adhesion via b1
(VLA-4) integrins. A, Activation of Rap1 is sufficient to induce
adhesion to VCAM. CD31 positive variant Jurkat cells were
transfected with 5 mg pG3-TK luciferase reporter plasmid
and empty vector (control), HA-tagged RapV12, H-RasV12,
R-RasV38 (10 mg each), C3G (10 mg each), or RapGAP-LIG (20
mg), and were allowed to adhere to immobilized VCAM (50 ng/
ml). Adherent cells and the percent of cells bound from five
(RapV12), three (C3G), or two (RasV12, R-RasV38, and Rap-
GAP-LIG) independent experiments performed in triplicate or
quadruplicate were quantitated and calculated as in Fig. 1. 30–
50% specific adhesion of control cells to VCAM was observed in
the presence of medium alone. Cells transfected with RapV12
(**P , 0.01) and C3G (*P , 0.05), but not RasV12 or R-RasV38,
bound at significantly higher levels than control cells. RapGAP
LIG, P , 0.1003. B, Rap1 signaling is required for CD31-depen-
dent adhesion to VCAM. CD31 WT cells were transfected with
5  mg pG3-TK-luciferase and 30 mg empty vector (control),
HA-tagged RapN17, RapGAP, RalGDS-RBD, or His-tagged
Spa1 were allowed to adhere to VCAM as in A in the absence
or presence of cross-linked anti-CD31 antibody PECAM 1.3
(top). Paired t tests of transfected cells revealed that cells trans-
fected with RapGAP (*P , 0.05), Spa1, and RBD (§P , 0.1)
had significantly lower adhesion than control unstimulated cells,
and that RapN17, RapGAP (P , 0.05), Spa1, and RBD (P , 0.1)
significantly blocked CD31-dependent adhesion. 
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RapGAP, and a second GAP for Rap1, Spa1 (Kurachi et al.,
1997), significantly reduced basal Jurkat cell adhesion to
VCAM, and strongly blocked CD31-dependent adhesion
(Fig. 4 B).
It has been reported previously that Ras regulates TCR-
stimulated lymphocyte adhesion to ICAM (O’Rourke et al.,
1998; Tanaka et al., 1999). As we failed to detect Ras acti-
vation by CD31, and RasV12 did not induce a clear in-
crease in adhesion to ICAM or VCAM, it is unlikely that
Ras mediates the main signaling pathway from CD31 stim-
ulation to integrin-mediated adhesion. However, overex-
pression of RasN17 did inhibit CD31-dependent adhesion
to VCAM (data not shown), suggesting that Ras might
also contribute to adhesion responses.
Integrin-dependent adhesion can be regulated by changes
in integrin surface expression, integrin surface distribution
(avidity), or induction of conformational changes that in-
crease integrin ligand affinity (Stewart and Hogg, 1996).
To investigate at which level Rap1 might influence cell ad-
hesion, we first examined if Rap signaling affected LFA-1
expression levels. Jurkat cells were cotransfected with
EGFP as a reporter marker, along with indicated Rap1
signaling pathway cDNA constructs. Staining of trans-
fected cells with anti-
 
b
 
2 integrin antibody revealed that
overexpression of RapV12, RapN17, RBD, RapGAP, or
RapGAP LIG failed to influence surface expression levels
of LFA-1 (Fig. 5 A). CD31 expression levels were also un-
affected (data not shown). Similarly, RapV12, RapGAP
LIG, RapGAP, and RapN17 failed to induce LFA-1 sur-
face clustering, as detected with the NKI-L16 antibody
(data not shown), although active RasV12 induced cluster-
ing of LFA-1, as previously reported (Tanaka et al., 1999).
The anti-
 
a
 
L integrin antibody mAb 24 recognizes a con-
formation-dependent ligand-induced epitope on LFA-1,
and induction of the mAb 24 epitope correlates with in-
creased LFA-1 affinity for ICAM (Dransfield and Hogg,
1989). TCR and TPA-induced mAb 24 epitope expression
previously have been found to be dependent on the pres-
ence of ICAM, suggesting that signals generated by TCR
and TPA facilitate weak basal interactions between LFA-1
and ICAM, stabilizing LFA-1 in a high-affinity conforma-
tion (Cabanas and Hogg, 1993). This conformational
change can also be induced by LFA-1 exposure to Mn
 
2
 
1
 
,
independently of “inside-out” signaling. We found that
anti-CD31 stimulation of Jurkat cells, or Jurkat cells trans-
 
Figure 5.
 
Rap signaling regulates ligand-induced conformational
changes in LFA-1. A. Expression levels of LFA-1 
 
b
 
2 integrin on
transfected cells. Jurkat JHMI cells were transiently transfected
with 1 
 
m
 
g pCMV-EGFP C1 reporter plasmid along with empty
vector (GFP) or the indicated cDNA constructs. Cells were se-
quentially stained with anti-
 
b
 
2 integrin antibody L15 and rabbit
anti–mouse Ig-RPE-Cy5 conjugate, and GFP-expressing cells
were analysed by flow cytometry. Values are presented as mean
fluorescent intensity (arbitrary units) normalized to 100% for
cells expressing GFP alone. B, Rap signaling is required for
CD31 and Mn
 
2
 
1
 
-induced conformational changes in LFA-1.
JHMI cells were transfected as in A and left unstimulated (con-
trol) or were stimulated for 30 min with anti-CD31 2H8 antibody
(CD31), followed by staining with the ligand-induced binding
anti-LFA-1 antibody mAb 24, as in Materials and Methods. Al-
ternatively, unstimulated cells were coincubated with mAb 24
and 400 
 
m
 
M MnCl
 
2
 
 (Mn). mAb 24 expression was assessed by
flow cytometry, and expression levels were normalized to 1 for
unstimulated GFP-alone cells in each experiment. Data repre-
sent the means and standard errors of the representative experi-
ments (GFP,
 
 n 
 
5 
 
4; RapV12 and RapN17, 
 
n 
 
5 
 
3; RapGAP LIG
and RBD,
 
 n 
 
5 
 
2). Statistically significant differences between
control and stimulated cells, and between stimulated transfected
cells are noted (*
 
P 
 
, 
 
0.01; **
 
P 
 
, 
 
0.05; 
 
§
 
P , 0.1). C, RapN17
blocks mAb 24 induction. The experiment was performed as in
B, but data represents the percent of mAb 24-expressing cells. D,
Rap signaling regulates Mn21-induced adhesion to ICAM. Jurkat
cells were transfected with luciferase reporter plasmid and indi-
cated constructs as in Fig. 3, and were allowed to adhere to
ICAM in absence or presence of 4 mM MnCl2, and the percent of
the specific adhesion was calculated as in Fig. 3, and normalized
to 100 for mock-transfected stimulated cells. Data represent the
average mean and error of two to four experiments, with each
construct performed in quadruplicate. Statistically significant dif-
ferences are indicated (*P , 0.01; **P , 0.05).Reedquist et al. Rap1 GTPase Regulates Lymphocyte Adhesion 1157
fected with GFP alone, resulted in an z1.5-fold increase in
mAb 24 expression (Fig. 5 B and data not shown), whereas
a 2.25–2.5-fold increase was observed in Mn21-treated
cells. Incubation of cells with mAb 24 at 48C abolished
CD31 and Mn21-induced mAb 24 expression to back-
ground levels (data not shown), consistent with the tem-
perature sensitivity of the mAb 24 epitope (Dransfield and
Hogg, 1989). Although RapV12 expression had no statisti-
cally significant effect on basal or induced mAb 24 epitope
expression, RapN17 and RBD abolished induction of the
mAb 24 epitope by CD31 and Mn21. Conversely, Rap-
GAP LIG enhanced CD31- and Mn21-induced expression
of the mAb 24 epitope. RapN17 also inhibited the increase
in the percentage of mAb 24-reactive cells observed after
CD31 or Mn21 treatment (Fig. 5 C). Thus, our studies sug-
gest that whereas Rap does not directly stimulate activa-
tion of LFA-1, signaling via Rap1, or basal activation of
Rap1, appears to be a requisite factor for stabilization of
the active conformation of LFA-1. Moreover, our finding
that RapN17 blocks direct conformational changes in-
duced by extracellular Mn21 may suggest that inactive
Rap may act to lock LFA-1 in an inactive conformation.
Consistent with this model, overexpression of RapN17,
RapGAP, or RalGDS RBD significantly blocked Mn21-
induced adhesion of Jurkat cells to immobilized ICAM,
whereas RapV12 augmented the induced cell adhesion
(Fig. 5 D).
Our report is the first example of requisite involvement
of Rap1 in coupling cell surface receptor stimulation to in-
tegrin-mediated adhesion. Previously, it was shown that
Rap1 is activated after stimulation of a large variety of cell
surface receptors, including B and T cell antigen receptors,
chemokine and cytokine receptors (including fMLP, PAF,
and GM-CSF), and receptors for platelet agonists (throm-
bin, thromboxane A2, and ADP; reviewed in Bos, 1997).
Many of these receptors have been implicated in the con-
trol of integrin-mediated adhesion. Furthermore, the in-
volvement of Rap1 in the control of cell adhesion recently
has been suggested by studies in which Spa1 was found to
inhibit G-CSF–induced adhesion of 32-D cells to culture
dishes (Tsukamoto et al., 1999). Also, FceRI-mediated ad-
hesion of RBL cells to culture dishes is inhibited by ex-
pression of RapGAP (M’Rabet, 1999). Therefore, it is
plausible to propose that one of the functions of Rap1 is to
control integrin-mediated adhesion.
The mechanism by which Rap1 signaling modulates in-
tegrin function is unknown, although our data suggest that
Rap1 may regulate the ability of LFA-1 to undergo ligand-
induced conformational changes. This effect could be di-
rect, by binding of Rap1 to integrins or integrin-associated
complexes. Interestingly, Rap2, a very close relative of
Rap1, has been found in complex with the aIIbb3 integrin
(Torti et al., 1999), although no extracellular stimuli cou-
pling to Rap2 activation have been identified. Alterna-
tively, Rap1 may stimulate effector pathways that regulate
integrins. Putative downstream signaling pathways of
Rap1 include B-Raf/MAP kinase cascade and Ral GTPase
GEFs (Bos, 1997, 1998), although we have not detected
CD31-dependent activation of MAP kinase or Ral in Jur-
kat cells (data not shown). Novel binding partners of acti-
vated Rap1 recently identified in vitro, Krit1 (Serebriiskii
et al., 1997) and AF6 (Linnemann et al., 1999), are pro-
teins lacking any obvious enzymatic activity and are
thought to associate with cytoskeletal components. Our
identification of integrin-adhesion as a physiological target
of Rap1 should facilitate identification of Rap1 effectors.
Finally, the unique coupling of CD31, which is also ex-
pressed on vascular cells, to Rap1 suggests a critical role
for Rap1 in mediating not only leukocyte adhesion, but
other integrin-dependent events mediated by CD31 that
require platelet and leukocyte interactions with vascular
endothelial cells, including leukocyte transmigration and
extravasation. Interestingly, regulation of integrin adhe-
sion might also explain the flat revertant phenotype of
Ras-transformed cells expressing Rap1 (Kitayama et al.,
1989).
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